University of Texas's MD Anderson Cancer Center: HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
September 12, 2022
September 12, 2022
HOUSTON, Texas, Sept. 12 -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 11, 2022:
* * *
MD Anderson presents patient-reported outcomes from DESTINY-Breast04 study
* * *
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to convention . . .
* * *
MD Anderson presents patient-reported outcomes from DESTINY-Breast04 study
* * *
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to convention . . .